Biomedica Solution

What Biomedica Solution does

Biomedica Solution is a privately held Japanese company founded on December 10, 2010, by Representative Director Nakao Atsushi. The company provides end-to-end infrastructure for the regenerative medicine and cell therapy sector, specializing in GMP-compliant cell culture processing facility (CPC) design, proprietary cell culture equipment, validation and sanitation services, outsourced quality testing, and facility operations management. It is headquartered in Ibaraki City, Osaka Prefecture, with a sales branch in Chiyoda-ku, Tokyo (relocated July 2024), and serves university hospitals, medical research institutions, pharmaceutical companies, and biotechnology firms across Japan.

The company's technology stack is anchored by proprietary in-house equipment: the AC800 large-scale CO2 incubator with integrated robot-hand transport, the AC408xy isolator-connectable CO2 incubator with automatic chamber transfer, the CSC series of closed safety cabinets with VHP decontamination, and the Cell Processing Integration Management System software for protocol-based, paperless operations. It also distributes the Applied Cells MARS cell separation line and supplies consumables such as gamma-sterilized cleanroom wipers (BM wiper-s) and humidification bags. Through its BMS-FACT facility in Osaka, the company holds a Specific Cell Processing Product Manufacturing License (FA5210002, issued November 29, 2021), enabling it to manufacture specific cell processing products for clinical research and physician-initiated trials. The company is also co-developing a blockchain/Web3-based cell culture management system with Jasmy Corporation, with the My Genome Guard project launched in April 2026 alongside Novacellum Corporation.

Biomedica Solution operates a direct enterprise sales model with no third-party distribution. Revenue is generated through capital equipment sales (incubators, freezers, CSC cabinets), quote-based professional services (validation DQ/IQ/OQ/PQ/PV, sanitation, maintenance, facility operations management), outsourced quality testing (sterility, endotoxin, mycoplasma, virus), and cell culture processing services. With 50 employees and approximately 20 years of operational heritage dating to Japan's first CPC, the company is positioned as a niche total-solution provider in Japan's regenerative medicine infrastructure stack.

Name

Biomedica Solution

Legal name

バイオメディカ・ソリューション株式会社

Website

https://bio-ms.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Biomedica Solution is a Japanese provider of GMP-compliant cell culture processing facility design, proprietary automated cell culture equipment, validation services, and outsourced quality testing, serving university hospitals, research institutions, and pharmaceutical/biotech firms in Japan's regenerative medicine sector.

Ownership category

akta.pro rank

Product category

Cell Culture Equipment and Regenerative Medicine Services

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Laboratory Apparatus & Furniture (3821), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Bioprocess Facility, Cleanroom & Utility Systems (HVAC, WFI, CIP/SIP, containment) (HLAAAJAJ)

akta.pro secondary industries

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), GMP Manufacturing Support Services (QA/QMS, validation, documentation) (HLAAAKAH)

Keywords

• Cell culture equipment
• Regenerative medicine services
• GMP facility design
• Cell processing validation
• Biomedical quality testing

Headquarters

HQ city

Ibaraki

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Cell Culture Facility Design and Proposal Services: Proposal and design of cell culture processing facilities based on GMP three principles, including isolator and automated culture equipment systems.
2. Validation and Sanitation Services: Validation services (DQ, IQ, OQ, PQ, PV) and sanitation (disinfection/sterilization) of cell culture facilities, including maintenance. Conducted both at client sites and at company's own facilities.
3. Quality Testing Services: Outsourced cell quality evaluation including sterility testing, endotoxin testing, mycoplasma testing, and other quality assays. Also includes human virus testing services.
4. Facility Operation Management Services: Cell culture facility operation management outsourcing, including documentation support, GMP-compliant management documents, and training.
5. Cell Culture Processing Services: End-to-end cell culture processing outsourcing including document creation, facility optimization, cell culture, performance/quality test setup and execution.
6. Equipment and Consumables Sales: Sale of cell culture equipment (incubators, freezers, CSC cabinets) and consumables (sterilized wipers, humidifier bags). Products include AC800, AC408xy, CSC series, cold storage containers, BM wiper-s.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Biomedica Solution designs, manufactures, and sells cell culture processing equipment (CO2 incubators, closed safety cabinets, low-temperature storage containers) and provides integrated services for regenerative medicine facilities, including GMP-compliant facility design, validation (DQ/IQ/OQ/PQ/PV), sanitation, quality testing (sterility, endotoxin, mycoplasma), and cell culture processing outsourcing. The company also offers the BMS-FACT cell processing facility and a proprietary cell processing integration management software system.

Product overview

Biomedica Solution is a regenerative medicine and cell therapy total support company offering equipment, software, and services. The core product portfolio includes the CSC series (closed safety cabinets) for aseptic environments, low temperature storage containers (refrigerators, freezers), AC408xy and AC800 CO2 incubators for automated cell culture, and Applied Cells MARS for cell separation. Supporting software includes the Cell Processing Integration Management System. Services encompass GMP-compliant facility design, quality testing (sterility, endotoxin, mycoplasma), cell culture processing, validation, sanitation, and maintenance. The company also offers consumables like sterilized wipers and humidification bags.

Differentiator

Problem solved

Functional benefit

Brands

• BMS-FACT (BMS Facility for Advanced Cell Technology): The company's proprietary cell culture processing facility at its Osaka headquarters, where the company conducts cell culture processing services under its Specific Cellular Processing Product Manufacturing License.

Products and services

• AC800 Large-scale Culture CO2 Incubator Auto-controlled robot hand integrated CO2 incubator for large-scale cell culture. Automatically transfers cell culture containers in and out of the incubator, includes built-in observation modules and waste disposal box, and maintains culture environment with CO2 forced ventilation.
• AC408xy Isolate CO2 Incubator (Auto-transfer) Isolate CO2 incubator with automatic transfer function that connects to isolators. Multiple independent chambers can be stored and automatically transferred to and from the isolator to prevent cross-contamination and cell mix-ups.
• CSC Series Closed Safety Cabinet Closed safety cabinet providing high-level aseptic environment with reliable decontamination via hydrogen peroxide vapor. Docks with cell culture CO2 incubators and centrifugal separation units. Includes CSC-18PS (single pass box) and CSC-18PD (double pass box) models.
• Low Temperature Storage Containers Complete lineup of cold storage solutions including medicinal refrigerators (BMR series), biomedical freezers (VH series), and ultra-low temperature freezers (BMF-U series) for various laboratory storage needs.
• Cell Processing Integration Management System Centralized management system for cell culture records, samples, reagents, and equipment. Features process management, user authority management, paperless operations with environmental monitoring data, and cell observation images. Includes integration with Jasmy blockchain via My Genome Guard project.
• GMP-compliant Cell Manufacturing Facility Design Service Cell manufacturing facility design services based on GMP three principles: human error prevention, contamination prevention, and quality assurance. Includes isolator systems, differential pressure management, zoning, and environmental monitoring.
• Cell Culture Facility Validation Services Validation services (DQ, IQ, OQ, PQ, PV) and sterilization validation for cell culture facilities, including maintenance. Conducted at both client sites and the company's own facilities.
• BMS-FACT Cell Processing Facility Service Cell culture processing facility (BMS Facility for Advanced Cell Technology) providing specific cell processing product manufacturing services under Specific Cell Processing Product Manufacturing License (Permit FA5210002). Located at Osaka headquarters.
• Cell Quality Testing Service Outsourced cell quality evaluation services including sterility testing, endotoxin testing, mycoplasma testing, and other quality assays such as human virus testing.
• Cell Culture Processing Service End-to-end cell culture processing outsourcing including document creation, facility optimization, cell culture, and performance/quality test setup and execution.
• Cell Culture Consumables (BM Humitainer and BM wiper-s) Original consumables including BM Humitainer (incubator humidification bags, gamma-sterilized) and BM wiper-s (cleanroom sterilized wipers with gamma irradiation and low particle generation).
• Cell Quality Testing Automation System Cell quality testing system utilizing Kawasaki Heavy Industries' robotics expertise combined with Biomedica Solution's quality testing know-how for automation of sterility, endotoxin, and mycoplasma testing.

Quantifiable outcome

• Contamination risk minimized through closed-system isolator technology and automated transport
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Novacellum CorporationcoreStrategic or Co-development Partner · 24 April 2026Novacellum Corporation, Biomedica Solution, and Jasmy Corporation jointly launched the My Genome Guard promotion project from fiscal year 2026. Details available at mygenomeguard.jasmy.co.jp.
• Azeas Co., Ltd. (アゼアス株式会社)minorChannel Partner/ Reseller/ Distributor · 20 March 2023Joint booth exhibition at the 22nd Japanese Society for Regenerative Medicine Annual Meeting (March 2023) to showcase Applied Cells MARS cell separation products.
• Jasmy Corporation (ジャスミー株式会社)coreStrategic or Co-development Partner · 4 August 2022Biomedica Solution and Jasmy are co-developing a cell culture integrated management system using Jasmy's blockchain platform and Web3 technology. The system aims to provide secure, transparent cell culture data management. Trial version was planned for early next year (2023). Expanded to My Genome Guard project launched 2026.
• Japan Agency for Medical Research and Development (AMED) - CiCLE ProgramcoreStrategic or Co-development Partner · 29 November 2021Biomedica Solution participates as a co-research and manufacturing facility under AMED's medical research innovation foundation creation (CiCLE) program for the research project 'Establishment of NY-ESO-1 high-function genome-edited T cell manufacturing foundation technology.' BMS-FACT facility was established for this clinical research and investigator-initiated trial manufacturing.
• Tera Pharmaceutical Co., Ltd. (テラ株式会社)minorOthers · 22 September 2017Tera Pharmaceutical was a group company holding all shares of Biomedica Solution. In September 2017, Biomedica Solution's board resolved to have Tera transfer all its shares back to Biomedica Solution (treasury stock acquisition).
• Yokohama City University and Shibuya Kogyo Co., Ltd. (渋谷工業株式会社)minorStrategic or Co-development Partner · 4 February 2015Joint development of iPS cell-derived organ manufacturing system, demonstrated at the 1st Regenerative Medicine Industrialization Expo in February 2015.
• Kawasaki Heavy Industries, Ltd. (川崎重工業株式会社)coreStrategic or Co-development Partner · 1 January 2013Joint development of cell quality testing automation systems since 2013, combining Kawasaki Heavy Industries' robotics expertise with Biomedica Solution's quality testing know-how. Resulting cell quality testing system was launched in 2017.
• Biomedica MP Co., Ltd. (株式会社バイオメディカ・エム・ピー)minorOthersAffiliated company listed on Biomedica Solution's homepage footer under affiliated companies.

Scale indicators5 records

Recent moves1 record

Direct peers

• PHC Holdings (formerly Panasonic Healthcare): Japan-headquartered manufacturer of CO2 incubators, biomedical freezers, ultra-low temperature freezers, and cell culture equipment directly overlapping with Biomedica's AC series incubators and BMR/VH/BMF-U cold storage lines. Closest direct competitor in the Japanese lab/biomedical equipment market.
• Shibuya Corporation: Japanese manufacturer of aseptic filling systems, isolators, and cleanroom equipment used in pharmaceutical and cell therapy manufacturing. Direct overlap with Biomedica's CSC series closed safety cabinets and isolator-based CPC designs (Shibuya Kogyo is also a documented partner on iPS cell-derived organ systems).
• Asahi Kasei Medical: Japan-based manufacturer of cell processing devices, virus removal filters, and Planova/Opus membrane systems used in regenerative medicine and bioprocessing. Comparable Japanese peer serving overlapping cell therapy customers with processing equipment and disposables.
• Miltenyi Biotec: German provider of cell separation and processing equipment (CliniMACS, MACS), cell culture reagents, and GMP-grade cell therapy manufacturing solutions. Direct competitor in cell processing equipment and outsourced cell processing services.
• Terumo BCT: Global leader in blood component and cell processing systems (e.g., Discover, Quantum cell expansion systems) widely adopted in cell therapy manufacturing. Direct competitor in the cell processing equipment space where Biomedica also sells processing services and equipment.
• Kawasumi Laboratories: Japanese manufacturer of cell processing bags, sterile disposable containers, and regenerative medicine processing devices. Closely comparable Japan-based peer serving the same cell therapy and regenerative medicine customer base.

Broad incumbents

• Cytiva (Danaher): Global bioprocessing incumbent offering cell culture media, single-use bioreactors, and process development services across upstream/downstream bioprocessing. Overlaps with Biomedica's bioprocess technology and facility design offerings but as part of a much broader portfolio.
• Lonza Group: Global CDMO with significant cell and gene therapy manufacturing services capacity. Comparable to Biomedica's outsourced cell culture processing and quality testing offerings, but at substantially larger scale and broader geographic footprint.
• Thermo Fisher Scientific: Broad life sciences incumbent providing CO2 incubators, cell culture media, bioreactors, QC reagents, and CDMO services. Competes with Biomedica across equipment (incubators/freezers) and quality testing services, though from a vastly larger scale.
• Sartorius AG: Global bioprocessing equipment and services provider (bioreactors, single-use systems, validation services). Comparable at the equipment and validation layer but operates at much larger scale with broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomedica Solution